CORCEPT THERAPEUTICS INC Logo

CORCEPT THERAPEUTICS INC

Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.

CORT | US

Overview

Corporate Details

ISIN(s):
US2183521028
LEI:
Country:
United States of America
Address:
101 REDWOOD SHORES PARKWAY, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of medications that modulate the effects of cortisol. The company's scientific approach centers on regulating cortisol activity at the glucocorticoid receptor (GR) to develop novel treatments for severe disorders. Its lead product, Korlym®, is approved for treating hyperglycemia associated with endogenous Cushing's syndrome. Corcept is advancing a broad clinical pipeline of selective cortisol modulators for a range of diseases across key therapeutic areas, including endocrinology, oncology, metabolism, and neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CORCEPT THERAPEUTICS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORCEPT THERAPEUTICS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORCEPT THERAPEUTICS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America KPTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.